Proprietary Algorithm Optimizes Site Selection Process to Help Clinical Trial Sponsors Reach Diversity Enrollment Targets
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) - Citeline announces the launch of Global Patient Insights, the industry's most comprehensive view of the worldwide patient landscape, designed to optimize the site selection process for clinical trial sponsors.
Global Patient Insights seamlessly integrates real-world data on patient population and diversity with Sitetrove's best-in-class site and investigator intelligence. This robust RWD dataset includes global electronic health records, census and epidemiology data, along with U.S. social determinants of health (SDOH) and medical claims data.
The race to develop a COVID-19 vaccine underscored the importance of diversity in clinical trials. Despite efforts to improve trial diversity by regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, clinical trials still lack representation among key racial and ethnic minority groups.
With Global Patient Insights, study sponsors will be able to easily locate sites with clinically relevant and diverse patient populations by:
- Prioritizing countries and global sites with higher volumes of clinically relevant patient populations
- Identifying U.S. physicians near investigators with access to the right patients for referrals
- Visualizing patient populations via dynamic dashboards and heatmaps
“Global Patient Insights takes Sitetrove to an exciting new level,” says Christina Masturzo, Citeline Vice President, Product Management. “For sponsors, it's the best of both worlds: our gold-standard Sitetrove data, coupled with information-rich real-world data. In fact, our product team refers to it as ‘Sitetrove on steroids.'
"Our goal at Citeline is to get the right treatments to the right patients at the right time. We do this by guiding sponsors throughout the drug development life cycle, from study design and protocol development through to site selection, patient recruitment and, ultimately, enrollment.”
Learn more about Citeline's Global Patient Insights at Citeline.com.
About Citeline
Citeline, a Norstella company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.
Citeline's global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering them with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the world's most trusted health science partners, visit Citeline and follow on LinkedIn and X.
Citeline PR contact:
Diffusion PR for Citeline
citeline@diffusionpr.com
(213) 318-4500
-
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cVANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a di2024-06-17
-
Indonesia Stock Exchange Partners with Nasdaq to Upgrade Market InfrastructureTechnology partnership will further enhance overall resilience and integrity of the exchange, while supporting the rapid deployment of new products2024-06-17
-
Adalvo 的 Liraglutide 預充式注射筆成為歐盟首款獲得批准的仿製藥馬爾他聖瓜安, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo 宣布 Liraglutide 預充式注射筆成功取得 DCP 批准,成為歐盟首款獲得批准的仿製藥。 根據 IQVIA 的報2024-06-17
-
促进生育,助力三胎——“三胎免费生”联合公益行动正式启动为积极响应国家号召实施三胎生育政策,扩大妇幼服务健康供给,在云南省优生优育妇幼保健协会指导下,昆明广播电视台联合昆明安琪儿妇产医院,于6月13日在昆明广播2024-06-17
-
学党史传承红色精神 守党纪筑牢自律防线——平安养老险湖南分公司党支部开展主题党日活动七一前夕,平安养老险湖南分公司党支部全体成员走进“千年学府、百年师范”——湖南第一师范,开展了一次学史明理、学史增信、学史崇德、学史力行的主题党日活动。重2024-06-17